These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 3053897)

  • 1. Lethal graft-vs-host disease induced by a class II MHC antigen only disparity is not mediated by cytotoxic T cells.
    Thiele DL; Bryde SE; Lipsky PE
    J Immunol; 1988 Nov; 141(10):3377-82. PubMed ID: 3053897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lethal graft-vs-host disease across major histocompatibility barriers: requirement for leucyl-leucine methyl ester sensitive cytotoxic T cells.
    Thiele DL; Charley MR; Calomeni JA; Lipsky PE
    J Immunol; 1987 Jan; 138(1):51-7. PubMed ID: 2946780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leucyl-leucine methyl ester treatment of donor cells permits establishment of immunocompetent parent----F1 chimeras that are selectively tolerant of host alloantigens.
    Thiele DL; Calomeni JA; Lipsky PE
    J Immunol; 1987 Oct; 139(7):2137-42. PubMed ID: 3309052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection from T helper cell-mediated graft-versus-host disease by the presence of an MHC class I alloantigen is associated with perturbation of MHC class II-restricted responses by class I-derived peptides.
    Leibnitz RR; Lipsky PE; Thiele DL
    J Immunol; 1995 Aug; 155(4):1784-95. PubMed ID: 7636234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of major histocompatibility complex and non-major histocompatibility complex encoded antigens in generation of bile duct lesions during hepatic graft-vs.-host responses mediated by helper or cytotoxic T cells.
    Williams FH; Thiele DL
    Hepatology; 1994 Apr; 19(4):980-8. PubMed ID: 8138273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerance induction of allo-class II H-2 antigen-reactive L3T4+ helper T cells and prolonged survival of the corresponding class II H-2-disparate skin graft.
    Hori S; Sato S; Kitagawa S; Azuma T; Kokudo S; Hamaoka T; Fujiwara H
    J Immunol; 1989 Sep; 143(5):1447-52. PubMed ID: 2527264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intestinal graft-versus-host disease is initiated by donor T cells distinct from classic cytotoxic T lymphocytes.
    Thiele DL; Eigenbrodt ML; Bryde SE; Eigenbrodt EH; Lipsky PE
    J Clin Invest; 1989 Dec; 84(6):1947-56. PubMed ID: 2531761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of leucyl-leucine methyl ester-sensitive cytotoxic cells in skin allograft rejection.
    Thiele DL; Geissler GH; Williams FH; Lipsky PE
    Transplantation; 1992 Jun; 53(6):1334-40. PubMed ID: 1604489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of T cell subsets in lethal graft-versus-host disease (GVHD) directed to class I versus class II H-2 differences. II. Protective effects of L3T4+ cells in anti-class II GVHD.
    Sprent J; Schaefer M; Korngold R
    J Immunol; 1990 Apr; 144(8):2946-54. PubMed ID: 1969878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic effect of murine cytomegalovirus on the induction of acute graft-vs-host disease involving MHC class I differences only. Analysis of in vitro T cell function.
    Via CS; Shanley JD; Shearer GM
    J Immunol; 1990 Nov; 145(10):3283-9. PubMed ID: 2172381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of L3T4+ and Lyt-2+ donor cells in graft-versus-host immune deficiency induced across a class I, class II, or whole H-2 difference.
    Moser M; Sharrow SO; Shearer GM
    J Immunol; 1988 Apr; 140(8):2600-8. PubMed ID: 3258615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leucyl-leucine methyl ester-treated haploidentical donor lymphocyte infusions can mediate graft-versus-leukemia activity with minimal graft-versus-host disease risk.
    Hsieh MH; Varadi G; Flomenberg N; Korngold R
    Biol Blood Marrow Transplant; 2002; 8(6):303-15. PubMed ID: 12108916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cell subsets involved in lethal graft-versus-host disease directed to immunodominant minor histocompatibility antigens.
    Berger M; Wettstein PJ; Korngold R
    Transplantation; 1994 Apr; 57(7):1095-102. PubMed ID: 7909395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of cytotoxic T lymphocytes in the prevention of lupus-like disease occurring in a murine model of graft-vs-host disease.
    Via CS; Sharrow SO; Shearer GM
    J Immunol; 1987 Sep; 139(6):1840-9. PubMed ID: 2957440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leu-Leu-OMe sensitivity of human activated killer cells: delineation of a distinct class of cytotoxic T lymphocytes capable of lysing tumor targets.
    Thiele DL; Lipsky PE
    J Immunol; 1986 Aug; 137(4):1399-406. PubMed ID: 3488348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clonal analysis of murine graft-vs-host disease. I. Phenotypic and functional analysis of T lymphocyte clones.
    Parkman R
    J Immunol; 1986 May; 136(10):3543-8. PubMed ID: 2871104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reactivity of hybridomas derived from T cells activated in vivo during graft-versus-host disease.
    Leibnitz RR; Lipsky PE; Thiele DL
    J Immunol; 1994 Dec; 153(11):4959-68. PubMed ID: 7963559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR; Majewski D; Hanson G
    Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dipeptidyl peptidase I is enriched in granules of in vitro- and in vivo-activated cytotoxic T lymphocytes.
    Brown GR; McGuire MJ; Thiele DL
    J Immunol; 1993 Jun; 150(11):4733-42. PubMed ID: 8496587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of polyinosinic:polycytidylic acid (pI:C) on the graft-vs-host (GVH) reaction. II. Increased NK-mediated rejection on C57BL/6 lymphocytes by (C57BL/6 X A)F1 mice.
    Peres A; Nestel FP; Seemayer TA; Lapp WS
    J Immunol; 1986 Dec; 137(11):3420-7. PubMed ID: 3537120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.